Effect on growth of long-term treatment with intranasal triamcinolone acetonide aqueous in children with allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [Ann Allergy Asthma Immunol] Journal article | | Title | Effect on growth of long-term treatment with intranasal triamcinolone acetonide aqueous in children with allergic rhinitis. | | Author(s) | Skoner DP, Gentile DA, Doyle WJ | | Institution | Division of Allergy, Asthma, and Immunology, Department of Pediatrics, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA. dskoner@wpahs.org | | Source | Ann Allergy Asthma Immunol 2008 Oct; 101(4):431-6. | | MeSH | Administration, Intranasal
Adolescent
Body Height
Child
Female
Glucocorticoids
Growth
Humans
Male
Patient Compliance
Rhinitis, Allergic, Perennial
Triamcinolone Acetonide
| | Abstract | BACKGROUND: Guidelines recommend treatment with intranasal corticosteroids for patients with allergic rhinitis (AR), but concerns remain about possible adverse effects.
OBJECTIVE: To present the 1- and 2-year growth results for children with AR treated with triamcinolone acetonide aqueous nasal spray.
METHODS: Thirty-nine children (aged 6.1-14.3 years at study entry) were treated with triamcinolone acetonide aqueous for 1 year, and a subset of 30 children completed a second year of treatment. The dose was physician titered to achieve control over AR symptoms. For each child, statural heights at baseline and at the 1- and 2-year (where available) visits, together with growth rates, were measured and were compared with predicted values.
RESULTS: There were no significant differences between measured and predicted heights at the 1- and 2-year visits. The mean (SD) measured--predicted difference was 0.3 (2.2) cm (95% confidence interval, -0.4 to 1.0 cm) at the 1-year visit and 0.5 (3.0) cm (95% confidence interval, -0.6 to 1.6 cm) at the 2-year visit. Mean differences in measured and predicted growth rates were nonsignificant at the 1- and 2-year visits.
CONCLUSIONS: Triamcinolone acetonide aqueous titered to control AR symptoms and given for 1 or 2 years had no significant effect on statural growth in children with AR. | | Language | eng | | Pub Type(s) | Journal Article
Research Support, Non-U.S. Gov't
| | PubMed ID | 18939734 |
|
|
| |
Advertise on this site.
| | |
|
